Please use this identifier to cite or link to this item:
|Title:||Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.|
Rose, A. M.
Vincent, D. F.
Ridgway, R. A.
Coates, P. J.
Dayal, J. H. S.
Spender, L. C.
Sapkota, G. P.
Purdie, K. J.
Proby, C. M.
Harwood, C. A.
Leigh, I. M.
South, A. P.
Sansom, O. J.
Inman, G. J.
|Publisher:||Nature Publishing Group|
|Citation:||Nature Communications, 2016 7:12493|
|Abstract:||Melanoma patients treated with oncogenic BRAF inhibitors can develop cutaneous squamous cell carcinoma (cSCC) within weeks of treatment, driven by paradoxical RAS/RAF/MAPK pathway activation. Here we identify frequent TGFBR1 and TGFBR2 mutations in human vemurafenib-induced skin lesions and in sporadic cSCC. Functional analysis reveals these mutations ablate canonical TGFb Smad signalling, which is localized to bulge stem cells in both normal human and murine skin. MAPK pathway hyperactivation (through BrafV600E or KrasG12D knockin) and TGFb signalling ablation (through Tgfbr1 deletion) in LGR5 þ ve stem cells enables rapid cSCC development in the mouse. Mutation of Tp53 (which is commonly mutated in sporadic cSCC) coupled with Tgfbr1 deletion in LGR5 þ ve cells also results in cSCC development. These findings indicate that LGR5 þ ve stem cells may act as cells of origin for cSCC, and that RAS/RAF/MAPK pathway hyperactivation or Tp53 mutation, coupled with loss of TGFb signalling, are driving events of skin tumorigenesis|
|Rights:||This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/|
|Description:||The WES data for the 30 samples have been deposited in the European Genome-phenome Archive under accession code EGAS00001001892. The authors declare that all other relevant data supporting the findings of this study are available within the article and its Supplementary Information files. Additional information can be obtained from the corresponding authors (G.J.I. and O.J.S.). Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications|
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Files in This Item:
|ncomms12493.pdf||Published (publisher PDF)||2.14 MB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.